As of 2024-12-12, the Relative Valuation of Cullinan Oncology Inc (CGEM) is (57.25) USD. This relative valuation is based on P/E multiples. With the latest stock price at 12.55 USD, the upside of Cullinan Oncology Inc based on Relative Valuation is -556.2%.
The range of the Relative Valuation is (53.54) - (49.94) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.7x - 31.7x | 26.7x |
| Forward P/E multiples | 19.2x - 20.3x | 19.8x |
| Fair Price | (53.54) - (49.94) | (57.25) |
| Upside | -526.6% - -497.9% | -556.2% |
| Date | P/E |
| 2024-12-04 | -5.26 |
| 2024-12-03 | -5.19 |
| 2024-12-02 | -5.34 |
| 2024-11-29 | -5.46 |
| 2024-11-27 | -5.31 |
| 2024-11-26 | -5.18 |
| 2024-11-25 | -5.09 |
| 2024-11-22 | -5.09 |
| 2024-11-21 | -4.96 |
| 2024-11-20 | -5.10 |
| 2024-11-19 | -5.31 |
| 2024-11-18 | -5.46 |
| 2024-11-15 | -5.62 |
| 2024-11-14 | -6.21 |
| 2024-11-13 | -6.41 |
| 2024-11-12 | -6.50 |
| 2024-11-11 | -7.01 |
| 2024-11-08 | -6.50 |
| 2024-11-07 | -6.32 |
| 2024-11-06 | -6.69 |
| 2024-11-05 | -6.48 |
| 2024-11-04 | -6.46 |
| 2024-11-01 | -6.40 |
| 2024-10-31 | -6.31 |
| 2024-10-30 | -6.58 |
| 2024-10-29 | -6.86 |
| 2024-10-28 | -6.55 |
| 2024-10-25 | -6.47 |
| 2024-10-24 | -6.43 |
| 2024-10-23 | -6.33 |
| 2024-10-22 | -6.47 |
| 2024-10-21 | -6.57 |
| 2024-10-18 | -6.80 |
| 2024-10-17 | -7.05 |
| 2024-10-16 | -7.14 |
| 2024-10-15 | -6.59 |
| 2024-10-14 | -6.58 |
| 2024-10-11 | -6.58 |
| 2024-10-10 | -6.44 |
| 2024-10-09 | -6.27 |
| 2024-10-08 | -6.54 |
| 2024-10-07 | -6.51 |
| 2024-10-04 | -6.63 |
| 2024-10-03 | -6.53 |
| 2024-10-02 | -6.69 |
| 2024-10-01 | -6.80 |
| 2024-09-30 | -6.79 |
| 2024-09-27 | -6.97 |
| 2024-09-26 | -7.02 |
| 2024-09-25 | -6.63 |